Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derivedno prior Q4 2019 on file Net Income-$6.29M-$6.29MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,331,000N/M Operating Cash Flowderived-$1,927,000N/M ended Dec 31, 2020 · filed Apr 16, 2021 · 106 d after period end